Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.

MLA

Autio, Karen A., et al. “Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.” Clinical Genitourinary Cancer, vol. 13, no. 4, Aug. 2015, pp. e305–09. EBSCOhost, https://doi.org/10.1016/j.clgc.2014.11.008.

APA

Autio, K. A., Farooki, A., Glezerman, I. G., Chan, A., Schneider, C. W., Barr, H. C., Seyboth, B. M., Kampel, L. J., Danila, D. C., Rathkopf, D. E., Slovin, S. F., Scher, H. I., & Morris, M. J. (2015). Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. Clinical Genitourinary Cancer, 13(4), e305–e309. https://doi.org/10.1016/j.clgc.2014.11.008

Chicago

Autio, Karen A, Azeez Farooki, Ilya G Glezerman, Amelia Chan, Coursen W Schneider, Hallie C Barr, Brian M Seyboth, et al. 2015. “Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.” Clinical Genitourinary Cancer 13 (4): e305–9. doi:10.1016/j.clgc.2014.11.008.